FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 718 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab August 11, 2022 Rare Identical Twins Born With Different Body Sizes Get Mistaken For... December 13, 2019 Reunión anual de la American Society of Clinical Oncology de 2022:... June 6, 2022 Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast... November 13, 2020 Load more HOT NEWS Presence of Tumour and Higher Levels of LAG3-positive T-cells in the... Efficacy Outcomes of Olaparib in Patients with mCRPC with BRCA Alterations... Estimate of the Global Economic Cost of the Most Prevalent Cancers... Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance
